The following is a summary of the ENDRA Life Sciences Inc. (NDRA) Q1 2024 Earnings Call Transcript:

Financial Performance:

• ENDRA Life Sciences has reported a decreased operating expense to $2.8 million in Q1 2024, primarily due to reduced research and development expenses.

• The company's net loss stood at $2.8 million, or $0.26 per share, an improvement from a net loss of $2.9 million or $0.93 per share in Q1 2023.

• The company's cash and cash equivalents totalled $1.1 million as of March 31, 2024.

Business Progress:

• ENDRA Life Sciences is targeting new clinical research sites and markets to gather clinical evidence for the TAEUS system.

• Regular interactions are being held with the FDA to meet the clinical requirements of their TAEUS systems De Novo application.

• They have installed the first TAEUS system in the United Kingdom and have expanded their global intellectual property portfolio with the issuance of eight additional patents.

• Opportunities for collaborations and strategic growth beyond liver disease are being actively explored.

More details: ENDRA Life Sciences IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.